{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-095472","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.091465+00:00","generated_at":"2026-06-03T23:07:25.016237+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data","bullets":["FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.","Approximately 30 participants dosed in study; no convulsions observed in any participant.","Company working with FDA to evaluate resolving the hold; prior guidance on NMRA-266 withdrawn.","NMRA-266 is an M4 muscarinic receptor PAM, part of Neumora's M4 PAM franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-095472","json":"https://secwatch.observer/filing/0001193125-24-095472.json","markdown":"https://secwatch.observer/filing/0001193125-24-095472.md","text":"https://secwatch.observer/filing/0001193125-24-095472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/0001193125-24-095472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/d805556d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:07:25.016237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}